Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer

• Published in: PloS one Vol. 7; no. 7; p. e37065
• Main Authors: Ho-Pun-Cheung, Alexandre, Bazin, Hervé, Gaborit, Nadège, Larbouret, Christel, Garnero, Patrick, Assenat, Eric, Castan, Florence, Bascoul-Mollevi, Caroline, Ramos, Jeanne, Ychou, Marc, Pèlegrin, André, Mathis, Gérard, Lopez-Crapez, Evelyne
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 19.07.2012; Public Library of Science (PLoS)
• Subjects: Activation; Animals; Bioassays; Biological assays; Biology; Breast cancer; Breast Neoplasms - metabolism; Cancer therapies; Cell Line, Tumor; Copy number; Dimerization; Energy consumption; Energy transfer; Epidermal growth factor; Epidermal growth factor receptors; ErbB-2 protein; FDA approval; Female; Fluorescence resonance energy transfer; Fluorescence Resonance Energy Transfer - methods; Humans; Immunoglobulins; In Vitro Techniques; Kinases; Laboratories; Ligands; Medical prognosis; Medicine; Metastasis; Mice; mRNA; Oncology; Patients; Protein expression; Protein Multimerization; Proteins; Receptor mechanisms; Receptor, Epidermal Growth Factor - metabolism; Receptor, ErbB-2 - chemistry; Receptor, ErbB-2 - metabolism; Receptors; Resonance; Rodents; Tumors; Tyrosine; Xenografts; France
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0037065

Following the development of targeted therapies against EGFR and HER2, two members of the human epidermal receptor (HER) family of receptor tyrosine kinases, much interest has been focused on their expression in tumors. However, knowing the expression levels of individual receptors may not be sufficient to predict drug response. Here, we describe the development of antibody-based time-resolved Förster resonance energy transfer (TR-FRET) assays for the comprehensive analysis not only of EGFR and HER2 expression in tumor cryosections, but also of their activation through quantification of HER homo- or heterodimers. First, EGFR and HER2 expression levels were quantified in 18 breast tumors and the results were compared with those obtained by using reference methods. The EGFR number per cell determined by TR-FRET was significantly correlated with EGFR mRNA copy number (P<0.0001). Moreover, our method detected HER2 overexpression with 100% specificity and sensibility, as confirmed by the standard IHC, FISH and qPCR analyses. EGFR and HER2 dimerization was then assessed, using as controls xenograft tumors from cell lines with known dimer expression profiles. Our results show that quantification of HER dimerization provides information about receptor activation that cannot be obtained by quantification of single receptors. Quantifying HER expression and dimerization by TR-FRET assays might help identifying novel clinical markers for optimizing patients' treatment in oncology.